...
首页> 外文期刊>Catheterization and cardiovascular interventions: Official journal of the Society for Cardiac Angiography & Interventions >Autologous cell-based therapy for ischemic heart disease: clinical evidence, proposed mechanisms of action, and current limitations.
【24h】

Autologous cell-based therapy for ischemic heart disease: clinical evidence, proposed mechanisms of action, and current limitations.

机译:基于自体细胞的缺血性心脏病治疗:临床证据,拟议的作用机制和目前的局限性。

获取原文
获取原文并翻译 | 示例

摘要

Cell-based therapy is a promising approach for cardiac repair in patients with coronary artery disease. In preclinical and early clinical studies, investigators have preliminary evidence showing that stem cell therapy can safely and effectively improve myocardial perfusion and left ventricular function. Cardiac stem cell therapy may decrease left ventricular remodeling in cases of myocardial infarction and may alleviate symptoms and prevent cardiac enlargement in chronic ischemic heart disease. Various mechanisms, including paracrine effects, are believed to contribute to stem cell-mediated cardiac repair. Further studies are needed to determine the optimal timing of therapy, best mode of delivery, and most effective cell dose. Cardiac stem cell therapy promises to become an important option for treating patients with coronary artery disease.
机译:基于细胞的疗法是冠状动脉疾病患者心脏修复的一种有前途的方法。在临床前和早期临床研究中,研究人员有初步证据表明,干细胞疗法可以安全有效地改善心肌灌注和左心室功能。在心肌梗塞的情况下,心脏干细胞疗法可以减少左心室重构,并可以缓解症状并预防慢性缺血性心脏病中的心脏增大。据信包括旁分泌作用在内的各种机制有助于干细胞介导的心脏修复。需要进一步的研究以确定最佳的治疗时机,最佳的分娩方式和最有效的细胞剂量。心脏干细胞疗法有望成为治疗冠心病患者的重要选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号